Gary Ulaner, MD, PhD

Dr. Gary Ulaner is the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy (MIT) at the Hoag Family Cancer Institute and Professor of Radiology and Translational Genomics at the University of Southern California.

Gary has been the principal investigator of prospective clinical trials for six novel PET radiotracers for patients with breast cancer, prostate cancer and myeloma, funded by two National Institutes of Health R01s, as well as grants from the Department of Defense (DoD) Breast Cancer Research Programs, Susan G. Komen Foundation, and Rising Tide Foundation. His clinical trials emphasize targeted imaging to guide targeted therapy of cancer, particularly ER, HER2, PSMA and CD38 targeted PET imaging.

Gary in on the editorial board of 4 leading radiology journals, authored the text “Fundamentals of Oncologic PET/CT”, and is on the scientific advisory boards of ImaginAb, GE Healthcare, and the Lobular Breast Cancer Alliance.

Gary currently lives in Irvine, California, with his wife, Alena, son, Ilya, and daughter, Anabel. He met his wife swing dancing, and they are still dancing today, albeit with less frequency.

• National Institutes of Health Cancer Biology Pre-Doctoral Fellowship, 1994
• National Institutes of Health Medical Scientist Training Program, 1997
• National Institutes of Health Post-Doctoral Fellowship, 2001
• RSNA Roentgen Resident Research Award, 2005
• Resident of the Year, University of Southern California, 2009
• RSNA Excellence Award for Research, 2011
• Susan Komen for the Cure Career Catalyst Award, 2012
• Department of Defense Breakthrough Award, 2014
• Radiographics Educational Design Award, 2015
• Radiology Editor’s Recognition Award with Special Distinction, 2015
• Radiology Editor’s Recognition Award with Special Distinction, 2016
• Jon Shevell Young Scientist Scholarship, Susan Komen Foundation, 2016
• SNMMI Best Breast Cancer Research Abstract, 2016
• SNMMI first place prize in Basic Science, 2016
• MSKCC Department of Radiology, Excellence in Teaching Award, 2016
• Weill Cornell Department of Radiology, Best Teacher, 2016
• Jon Shevell Award from the Susan Komen Foundation, 2017
• Clinical Nuclear Medicine Editor’s Award, 2017
• Elected Fellow, American College of Nuclear Medicine, 2017
• First Hal O’Brien Rising Star Award, Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2018
• American College of Nuclear Medicine – President’s Award, 2019
• James and Pamela Muzzy Endowed Chair, 2021

• Rutgers University, New Brunswick, NJ — BA — 05/1993 — Biology
• Stanford University School of Medicine, Stanford, CA — MD, PhD — 06/2000 — Cancer Biology
• Johns Hopkins , Baltimore, MD — 06/2001 — Internship
• University of Southern California, Los Angeles, CA — 06/2009 — Diagnostic Radiology
• University of Southern California, Los Angeles, CA — 06/2009 — Nuclear Medicine

• Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms
  NIH · R37CA259260 · Apr 1, 2021 – Mar 31, 2026 · Role: Co-Investigator
• Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.
  NIH · R21CA256280 · Dec 9, 2020 – Nov 30, 2022 · Role: Co-Investigator
• CD38-targeted immunoPET of myeloma: Phase 2 trial of clinical applications
  NIH · R01CA248398 · Jul 1, 2020 – Jan 31, 2024 · Role: Principal Investigator
• The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab
  NIH · R01CA204167 · Apr 1, 2016 – Mar 31, 2021 · Role: Co-Investigator

• Molecular Imaging and Therapy
• PET/CT
• Estrogen Receptor-targeted imaging
• PSMA-targeted imaging and therapy
• HER2-targeted imaging
• CD38-targeted imaging
• Translational Genomics

• What’s New in Cancer Care.
• Hoag Memorial Hospital Emerges as Southern California Leader in Molecular Imaging & Therapy Research & Care
• FDG-PET/CT shows promise for breast cancer patients younger than 40
• FDG-PET/CT shows promise for breast cancer patients younger than 40
• 18F-FDG PET-CT reveals 33% of previously undetected male breast cancer
• The Utility of FDG-PET in the Treatment of Hodgkin Lymphoma
• Hoag launches PET trials for prostate cancer, myeloma
• Hoag Memorial Hospital Makes Moves to Become National Leader In Molecular Imaging: Moving Closer to Precision Therapies
• Going to the molecular level to think big about cancer
• Hoag is first in the United States to offer the CD38-Targeted Immuno PET myeloma trial, funded by the National Institutes of Health

• Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer. 2026 Jul; 8(4):e250732.. View in PubMed
• Erratum for: 61Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of 61Cu-labeled PET Radiotracers. Radiology. 2026 Jul; 320(1):e269013.. View in PubMed
• Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [225Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs. J Nucl Med. 2026 Jun 04.. View in PubMed
• HER2-targeted PET/CT in breast cancer: a systematic review of lesion-level concordance with pathology. Eur J Radiol. 2026 Sep; 202:112961.. View in PubMed
• 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study. Clin Cancer Res. 2026 May 15; 32(10):1973-1982.. View in PubMed
• Widespread Prostate Cancer Osseous Metastases: Negative on 18F-Piflufolastat PET but Positive on 18F-Fluciclovine PET. J Nucl Med. 2026 May 06.. View in PubMed
• CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study. J Immunother Cancer. 2026 Mar 27; 14(3).. View in PubMed
• ACR Appropriateness Criteria® Staging and Follow-Up of Adrenal Cancer. J Am Coll Radiol. 2026 Mar 21.. View in PubMed
• Targeted immunoPET imaging of multiple myeloma. Semin Hematol. 2025 Oct; 62(5):400-408.. View in PubMed
• ACR Appropriateness Criteria® Breast Implant Evaluation: Update 2025. J Am Coll Radiol. 2026 Apr; 23(4):658-680.. View in PubMed
• 61Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of 61Cu-labeled PET Radiotracers. Radiology. 2025 12; 317(3):e251151.. View in PubMed
• ACR Appropriateness Criteria® Female Breast Cancer Screening: 2025 Update. J Am Coll Radiol. 2025 Nov; 22(11S):S508-S530.. View in PubMed
• RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. Cancer Cell. 2026 Jan 12; 44(1):203-220.e8.. View in PubMed
• The Van Nuys DCIS Prognostic Index →The Silverstein DCIS Prognostic Index. Ann Surg Oncol. 2025 Dec; 32(13):9475-9477.. View in PubMed
• Enhanced contrast in FAP-targeting PET imaging with 61Cu-labeled FAP inhibitors: development and preclinical evaluation of novel [61Cu]Cu-Kalios PET radioligands. EJNMMI Radiopharm Chem. 2025 Aug 21; 10(1):55.. View in PubMed
• Detection of Oligometastatic Disease in Breast Cancer: It’s the Little Things That Count. Radiology. 2025 Aug; 316(2):e251797.. View in PubMed
• Summary: Appropriate Use Criteria for 18F-FDG PET/CT for Initial Staging of Malignant Disease. J Nucl Med. 2025 Jul 01; 66(7):1034-1038.. View in PubMed
• Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis. J Nucl Med. 2025 06 02; 66(6):873-879.. View in PubMed
• Evaluating Automated Tools for Lesion Detection on 18F Fluoroestradiol PET/CT Images and Assessment of Concordance with Standard-of-Care Imaging in Metastatic Breast Cancer. Radiol Imaging Cancer. 2025 05; 7(3):e240253.. View in PubMed
• 18F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis. J Nucl Med. 2025 05 01; 66(5):692-699.. View in PubMed
• ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density: 2024 Update. J Am Coll Radiol. 2025 May; 22(5S):S405-S423.. View in PubMed
• [18F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast Cancer. J Clin Oncol. 2025 Jun 10; 43(17):1942-1947.. View in PubMed
• CD38-Targeted 89Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care. J Nucl Med. 2025 Mar 03; 66(3):482.. View in PubMed
• Editorial Commentary: Should “heterogeneous response” be considered as new category for assessing treatment response in patients with breast cancer? Eur J Nucl Med Mol Imaging. 2025 Feb; 52(3):801-805 . View in PubMed
• High PSMA Avidity, Yet Still Benign: The Importance of CT Morphology for Diagnosing Fibrous Dysplasia on PSMA-Targeted PET/CT. Clin Nucl Med. 2025 Apr 01; 50(4):358-359.. View in PubMed
• Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines. Breast. 2024 Dec; 78:103806.. View in PubMed
• 61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging. J Nucl Med. 2024 09 03; 65(9):1427-1434.. View in PubMed
• Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies. J Nucl Med. 2024 08 01; 65(8):1239-1243.. View in PubMed
• International survey on invasive lobular breast cancer identifies priority research questions. NPJ Breast Cancer. 2024 Jul 20; 10(1):61.. View in PubMed
• Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma. Eur J Nucl Med Mol Imaging. 2024 Nov; 51(13):4073-4082.. View in PubMed
• Dotatate PET/CT and 225Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer. Radiology. 2024 07; 312(1):e233408.. View in PubMed
• ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer. JAMA Netw Open. 2024 07 01; 7(7):e2423435.. View in PubMed
• Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines. Eur J Nucl Med Mol Imaging. 2024 07; 51(9):2701-2705.. View in PubMed
• ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update. J Am Coll Radiol. 2024 Jun; 21(6S):S126-S143.. View in PubMed
• ACR Appropriateness Criteria® Imaging of Invasive Breast Cancer. J Am Coll Radiol. 2024 Jun; 21(6S):S168-S202.. View in PubMed
• HER2-targeted PET for Patients with Breast Cancer: Scintillating Data. Radiology. 2024 06; 311(3):e240814.. View in PubMed
• 111 In-Pentetreotide-Guided Radiosurgery for Intraoperative Localization of Retroperitoneal Nodal Metastasis in a Patient With Ileal Neuroendocrine Tumor. Clin Nucl Med. 2024 Jul 01; 49(7):695-697.. View in PubMed
• Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024 07; 51(9):2706-2732.. View in PubMed
• Negative 18 F-Piflufolastat PET/CT, But Positive 18 F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer. Clin Nucl Med. 2024 Oct 01; 49(10):968-970.. View in PubMed
• Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy. Br J Haematol. 2024 Jul; 205(1):127-137.. View in PubMed
• First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. J Nucl Med. 2024 03 01; 65(3):386-393.. View in PubMed
• Women’s Health Update: Growing Role of PET for Patients with Breast Cancer. Semin Nucl Med. 2024 03; 54(2):247-255.. View in PubMed
• Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[18F]Fluoro-17β-Estradiol PET. J Nucl Med. 2024 02 01; 65(2):221-223.. View in PubMed
• Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer. PET Clin. 2024 Apr; 19(2):147-162.. View in PubMed
• 18F-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies-AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2024 10; 223(4):e2330330.. View in PubMed
• ACR Appropriateness Criteria® Breast Implant Evaluation: 2023 Update. J Am Coll Radiol. 2023 11; 20(11S):S329-S350.. View in PubMed
• Detection of Biochemically Recurrent Prostate Cancer with [18F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters. Tomography. 2023 08 15; 9(4):1504-1514.. View in PubMed
• Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis. Blood Adv. 2023 08 08; 7(15):3984-3992.. View in PubMed
• Value of subspecialist second opinion reads of 18 F-FDG PET-CT examinations for patients with breast cancer. Nucl Med Commun. 2023 Sep 01; 44(9):825-829.. View in PubMed
• Metabolic Positron Emission Tomography in Breast Cancer. PET Clin. 2023 Oct; 18(4):473-485.. View in PubMed
• Other Novel PET Radiotracers for Breast Cancer. PET Clin. 2023 Oct; 18(4):557-566.. View in PubMed
• CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition. Leukemia. 2023 08; 37(8):1737-1740.. View in PubMed
• Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and Opportunities. PET Clin. 2023 Oct; 18(4):543-555.. View in PubMed
• Breast Cancer: Advances in Molecular Imaging. PET Clin. 2023 10; 18(4):xiii-xiv.. View in PubMed
• Evaluation of Treatment Response in Patients with Breast Cancer. PET Clin. 2023 Oct; 18(4):517-530.. View in PubMed
• Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer. PET Clin. 2023 Oct; 18(4):531-542.. View in PubMed
• Molecular Classification of Breast Cancer. PET Clin. 2023 Oct; 18(4):441-458.. View in PubMed
• ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S125-S145.. View in PubMed
• ACR Appropriateness Criteria® Palpable Breast Masses: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S146-S163.. View in PubMed
• Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol. J Nucl Med. 2023 03; 64(3):351-354.. View in PubMed
• Breast Cancer and Physiologic Avidity From Breast Feeding on FDG PET/CT. Clin Nucl Med. 2023 May 01; 48(5):420-421.. View in PubMed
• A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment. Clin Nucl Med. 2023 Apr 01; 48(4):e202-e203.. View in PubMed
• ACR Appropriateness Criteria® Imaging After Breast Surgery. J Am Coll Radiol. 2022 11; 19(11S):S341-S356.. View in PubMed
• ACR Appropriateness Criteria® Evaluation of Nipple Discharge: 2022 Update. J Am Coll Radiol. 2022 11; 19(11S):S304-S318.. View in PubMed
• False-Positive for Pulmonary Emboli on Ventilation/Perfusion Scan Due to Improper Patient Positioning During Tracer Administration. Clin Nucl Med. 2023 Jan 01; 48(1):95-97.. View in PubMed
• A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa. Clin Nucl Med. 2023 Jan 01; 48(1):e26-e27.. View in PubMed
• 18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation. Radiology. 2022 11; 305(2):419-428.. View in PubMed
• AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nat Commun. 2022 07 15; 13(1):4116.. View in PubMed
• High-resolution and high-sensitivity PET for quantitative molecular imaging of the monoaminergic nuclei: A GATE simulation study. Med Phys. 2022 Jul; 49(7):4430-4444.. View in PubMed
• 16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer. Semin Nucl Med. 2022 09; 52(5):574-583.. View in PubMed
• Value of MRI in evaluating urachal carcinoma: A single center retrospective study. Urol Oncol. 2022 07; 40(7):345.e9-345.e17.. View in PubMed
• Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. J Clin Oncol. 2022 03 20; 40(9):997-1008.. View in PubMed
• Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 10 01; 27(19):5195-5212.. View in PubMed
• CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. J Nucl Med. 2022 05; 63(5):720-726.. View in PubMed
• Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change? J Natl Compr Canc Netw. 2021 08 01; 19(8):xxx. Groheux D, Hindié E, Espié M, Ulaner GA . View in PubMed
• Evidence-Based Best Practices: 18F-FDG PET Staging of Newly Diagnosed Breast Cancer. Clin Nucl Med. 2021 07 01; 46(7):569-570.. View in PubMed
• Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. Neurology. 2021 06 08; 96(23):1091-1093.. View in PubMed
• 18F-FDG-Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT. Clin Nucl Med. 2021 May 01; 46(5):433-434.. View in PubMed
• Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. J Nucl Med. 2021 Sep 01; 62(9):1278-1284.. View in PubMed
• Author Correction: Accelerated single cell seeding in relapsed multiple myeloma. Nat Commun. 2021 Jan 20; 12(1):591.. View in PubMed
• Improved image reconstruction of 89Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm. EJNMMI Phys. 2021 Jan 19; 8(1):6.. View in PubMed
• Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. J Nucl Med. 2021 01; 62(1):6-14.. View in PubMed
• Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):230-237.e12.. View in PubMed
• Diffusion and Perfusion MRI Predicts Response Preceding and Shortly After Radiosurgery to Brain Metastases: A Pilot Study. J Neuroimaging. 2021 03; 31(2):317-323.. View in PubMed
• 18F-FDG PET/CT Helps Differentiate Peripheral Nerve Myeloid Sarcoma From a Presumed Benign Nerve Sheath Tumor. Clin Nucl Med. 2020 Dec; 45(12):989-991.. View in PubMed
• The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. Cancers (Basel). 2020 Nov 03; 12(11).. View in PubMed
• Extramedullary Myeloma of the Uterus on 18F-FDG PET/CT: A Rare Manifestation of Multiple Myeloma. Clin Nucl Med. 2020 Nov; 45(11):873-875.. View in PubMed
• Malignant perivascular epithelioid cell tumor of the ileum on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography with pathological correlation. World J Nucl Med. 2021 Apr-Jun; 20(2):208-210.. View in PubMed
• 18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. Eur J Nucl Med Mol Imaging. 2021 04; 48(4):1154-1165.. View in PubMed
• Acute Aortic Dissection Initially Suspected on 18F-FDG PET/CT. Clin Nucl Med. 2020 Oct; 45(10):819-820.. View in PubMed
• Clinical Utility of 18F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma. J Nucl Med. 2021 05 10; 62(5):643-647.. View in PubMed
• Mucinous urachal adenocarcinoma: A potential nonfluorodeoxyglucose-avid pitfall on 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography. World J Nucl Med. 2020 Oct-Dec; 19(4):432-434.. View in PubMed
• Laboratory-Proven Asymptomatic SARS-CoV-2 (COVID-19) Infection on 18F-FDG PET/CT. Clin Nucl Med. 2020 Aug; 45(8):654-655.. View in PubMed
• Accelerated single cell seeding in relapsed multiple myeloma. Nat Commun. 2020 07 17; 11(1):3617.. View in PubMed
• Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. J Nucl Med. 2021 03; 62(3):326-331.. View in PubMed
• Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Rev. 2021 03; 46:100732.. View in PubMed
• Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro Oncol. 2020 07 07; 22(7):979-992.. View in PubMed
• Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT. Radiology. 2020 08; 296(2):370-378.. View in PubMed
• Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. Clin Nucl Med. 2020 Jun; 45(6):e260-e266.. View in PubMed
• CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology. 2020 06; 295(3):606-615.. View in PubMed

• Jadvar, Hossein